Vestal Point Capital »

Protagonist Therapeutics shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $34M 326k 105.40

More positions owned by Vestal Point Capital

Revolution Medicines (RVMD)
BioMarin Pharmaceutical (BMRN)
Abivax SA Sponsored Ads (ABVX)
Neurocrine Biosciences (NBIX)
Arrowhead Pharmaceuticals (ARWR)
Enliven Therapeutics (ELVN)
Repligen Corporation (RGEN)
Bicara Therapeutics (BCAX)
Nurix Therapeutics (NRIX)
Apogee Therapeutics (APGE)
Ascendis Pharma A/S Sponsored Adr (ASND)
Immunocore Holdings Ads (IMCR)
Taysha Gene Therapies Com Shs (TSHA)
Dyne Therapeutics (DYN)
Sanofi SA Sponsored Adr (SNY)

View all positions for Vestal Point Capital

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Vanguard Group
UBS Group
Rtw Investments
Vanguard Portfolio Management
State Street Corporation
Wellington Management Company
Henderson Group
Johnson & Johnson
Invesco
Geode Capital Management
Citadel Advisors
Woodline Partners
Bank of America Corporation

View all funds holding Protagonist Therapeutics